{
    "Clinical Trial ID": "NCT00493636",
    "Intervention": [
        "INTERVENTION 1: ",
        "  A (Sorafenib + Gemcitabine or Capecitabine)",
        "  Sorafenib will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours); Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle; Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily, within 30 minutes after a meal, for 14 days followed by a 7 day rest period (without capecitabine)",
        "  Gemcitabine: Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle",
        "  Sorafenib: Sorafenib will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours)",
        "  Capecitabine: Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily, within 30 minutes after a meal, for 14 days followed by a 7 day rest period (without capecitabine).",
        "INTERVENTION 2: ",
        "  B (Placebo + Gemcitabine or Capecitabine)",
        "  Placebo will be administered ( 2 tablets ) orally twice daily (approximately every 12 hours); Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle; Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily, within 30 minutes after a meal, for 14 days followed by a 7 day rest period (without capecitabine)",
        "  Gemcitabine: Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle",
        "  Placebo: Placebo will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours)",
        "  Capecitabine: Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily, within 30 minutes after a meal, for 14 days followed by a 7 day rest period (without capecitabine)."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Histologically or cytologically confirmed adenocarcinoma of the breast.",
        "  Measurable or evaluable locally advanced or metastatic disease.",
        "  Age 18 years.",
        "  Disease progression during or after treatment with a bevacizumab-containing regimen in the adjuvant or first-line metastatic setting.",
        "  Patients must have discontinued chemotherapy at least 3 weeks prior to randomization.",
        "  No more than one prior chemotherapy regimen for locally advanced or metastatic disease.",
        "  Prior hormonal therapy allowed provided it has been discontinued prior to randomization.",
        "  Prior radiation therapy is allowed but must be completed at least 3 weeks prior to randomization. Previously radiated area(s) must not be the only site of disease.",
        "  ECOG Performance Status of 0 or 1.",
        "  Adequate bone marrow, liver, and renal function",
        "  Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to randomization, and must agree to use adequate contraception prior to study entry, for the duration of study participation and 28 days after the last study drug dosing.",
        "  Patients must be able and willing to sign a written informed consent.",
        "  Patients must be able to swallow and retain oral medication.",
        "Exclusion Criteria:",
        "  Patients with breast cancer over-expressing human epidermal growth factor receptor 2 (HER-2) (gene amplification by FISH or 3+ over-expression by immunohistochemistry). Patients with unknown HER-2 status are not eligible.",
        "  Patients with active brain metastases.",
        "  Major surgery, open biopsy, or significant traumatic injury within 4 weeks of randomization.",
        "  Prior use of gemcitabine/capecitabine or sorafenib.",
        "  Evidence or history of bleeding diathesis or coagulopathy.",
        "  Serious, non-healing wound, ulcer, or bone fracture.",
        "  Substance abuse, or medical, psychological, or social condition that may interfere with the patient's participation in the study or evaluation of the study results.",
        "  Use of cytochrome P450 enzyme-inducing anti-epileptic drugs is not allowed.",
        "  Clinically significant cardiac disease",
        "  Uncontrolled hypertension",
        "  Thrombolic, embolic, venous, or arterial events such as a cerebrovascular accident including transient ischemic attacks within the past 6 months.",
        "  Pulmonary hemorrhage/bleeding event > NCI-CTCAE Grade 2 within 4 weeks of randomization.",
        "  Any other hemorrhage/bleeding event  NCI-CTCAE Grade 3 within 4 weeks of randomization.",
        "  Active clinically serious infection > NCI-CTCAE Grade 2.",
        "  Known HIV infection or chronic hepatitis B or C (the safety and effectiveness of sorafenib in this patient population have not been studied).",
        "  Previous or concurrent cancer that is distinct in primary site or histology from breast cancer EXCEPT cervical cancer in-situ, treated basal cell carcinoma, superficial bladder tumors [Ta and Tis] or any cancer curatively treated > 5 years prior to randomization.",
        "  Known or suspected allergy to sorafenib or gemcitabine/capecitabine.",
        "  Prior or concurrent use of St. John's Wort or rifampin (rifampicin) within 3 weeks of randomization.",
        "  Concurrent anti-cancer therapy other than gemcitabine/capecitabine and sorafenib/placebo.",
        "  Prior treatment with any agent that targets VEGF or VEGFR (licensed or investigational), except bevacizumab.",
        "  Women who are pregnant or breast-feeding.",
        "  Use of any investigational drug within 30 days or 5 half-lives, whichever is longer, preceding randomization.",
        "  Inability to comply with protocol and/or not willing or not available for follow-up assessments.",
        "  Any condition which in the investigator's opinion makes the patient unsuitable for the study participation."
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Progression Free Survival",
        "  [Not Specified]",
        "  Time frame: From the date of randomization to date of first documented disease progression (i.e., the date on which a radiologic procedure or clinical evaluation was performed) or the date of death due to any cause, if before progression, assessed up to 39 months.",
        "Results 1: ",
        "  Arm/Group Title: A (Sorafenib + Gemcitabine or Capecitabine)",
        "  Arm/Group Description: Sorafenib will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours); Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle; Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily, within 30 minutes after a meal, for 14 days followed by a 7 day rest period (without capecitabine)",
        "  Gemcitabine: Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle",
        "  Sorafenib: Sorafenib will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours)",
        "  Capecitabine: Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily, within 30 minutes after a meal, for 14 days followed by a 7 day rest period (without capecitabine).",
        "  Overall Number of Participants Analyzed: 81",
        "  Median (95% Confidence Interval)",
        "  Unit of Measure: Days  103        (83 to 128)",
        "Results 2: ",
        "  Arm/Group Title: B (Placebo + Gemcitabine or Capecitabine)",
        "  Arm/Group Description: Placebo will be administered ( 2 tablets ) orally twice daily (approximately every 12 hours); Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle; Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily, within 30 minutes after a meal, for 14 days followed by a 7 day rest period (without capecitabine)",
        "  Gemcitabine: Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle",
        "  Placebo: Placebo will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours)",
        "  Capecitabine: Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily, within 30 minutes after a meal, for 14 days followed by a 7 day rest period (without capecitabine).",
        "  Overall Number of Participants Analyzed: 79",
        "  Median (95% Confidence Interval)",
        "  Unit of Measure: Days  81        (48 to 95)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 32/79 (40.51%)",
        "  Febrile neutropenia * 2/79 (2.53%)",
        "  Neutropenia * 0/79 (0.00%)",
        "  Vomiting * 3/79 (3.80%)",
        "  Abdominal pain * 1/79 (1.27%)",
        "  Nausea * 2/79 (2.53%)",
        "  Diarrhea * 2/79 (2.53%)",
        "  Constipation * 0/79 (0.00%)",
        "  Stomatitis * 2/79 (2.53%)",
        "  Disease progression * 2/79 (2.53%)",
        "  Pyrexia * 1/79 (1.27%)",
        "  Fatigue * 3/79 (3.80%)",
        "  Mucosal inflammation * 2/79 (2.53%)",
        "Adverse Events 2:",
        "  Total: 28/77 (36.36%)",
        "  Febrile neutropenia * 0/77 (0.00%)",
        "  Neutropenia * 2/77 (2.60%)",
        "  Vomiting * 2/77 (2.60%)",
        "  Abdominal pain * 3/77 (3.90%)",
        "  Nausea * 2/77 (2.60%)",
        "  Diarrhea * 1/77 (1.30%)",
        "  Constipation * 2/77 (2.60%)",
        "  Stomatitis * 0/77 (0.00%)",
        "  Disease progression * 2/77 (2.60%)",
        "  Pyrexia * 3/77 (3.90%)",
        "  Fatigue * 0/77 (0.00%)",
        "  Mucosal inflammation * 0/77 (0.00%)"
    ]
}